在患有耐火性过活膀的患者中,连续的第三线疗法的结果
Po-Ming Chow1,2,3, Tyler Trump1, Howard B Goldman1
1Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
概括
圣神经调节 (SNM) 和本质毒素A (BoNTA) 是对过度活跃膀 (OAB) 的有效第二三线治疗方法. 脊柱病理可能会降低后SNM BoNTA的有效性.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 过度活性膀 (OAB) 是一种影响生活质量的疾病.
- 圣神经调节 (SNM) 和本质毒素A (BoNTA) 已成为耐火性OAB的第三线治疗方法.
- 关于这些疗法的连续使用的数据有限.
研究的目的:
- 为了评估SNM在BoNTA治疗后 (BoNTA后SNM) 的疗效.
- 在SNM治疗后评估BoNTA的有效性 (后SNMBoNTA).
- 为了确定影响治疗反应和持续时间的因素,在连续的OAB疗法.
主要方法:
- 在2013-2022年期间接受SNM和BoNTA的172名OAB患者的回顾性审查.
- 主要终点:第二次第三线治疗的响应率 (>50%的改善).
- 二级终点:达到完全干燥的比例,治疗持续时间,以及反应/持续时间的风险因素.
主要成果:
- 在62.5%的SNM后BoNTA患者和61.8%的SNM后BoNTA患者中观察到显著的治疗反应.
- 实现完全干燥的患者比例分别为21.2%和23.5%.
- 在SNM后的BoNTA组中,脊椎病理与较低的响应率有关 (48.9%与73.7%相比).
结论:
- 对于耐火性OAB患者来说,SNM和BoNTA都是可行的顺序治疗选择.
- 序列疗法可显著改善症状,显著比例的患者达到完全干燥.
- 脊柱病理可能对SNM后接受BoNTA的患者的结果产生负面影响.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
161
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
161
01:21Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
197
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
197
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
442
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
442
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
198
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
198
01:24Cholinergic Antagonists: Pharmacokinetics
436
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
436